Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Benefits of Radiation Therapy Outweigh Risks of a Second Cancer: Study

Posted Mar 29 2011 1:00pm
healthnewslink

Likelihood that radiotherapy will cause another tumor is low, researchers say.

By Steven Reinberg
HealthDay Reporter

TUESDAY, March 29 (HealthDay News) -- The odds a second cancer will develop after radiation treatment for a first cancer are relatively low, U.S. National Cancer Institute researchers report.

In a long-term study of more than 600,000 cancer survivors, an estimated 8 percent of second cancers were attributable to radiation treatment for the original cancer, according to the study.

The results suggest that other factors, such as lifestyle risks and genetics, cause the majority of second cancers, the researchers say.

"The findings can be used by physicians to really put the risks into perspective when they are talking treatment options with their patients," said lead researcher Amy Berrington de Gonzalez, an investigator in the NCI's radiation epidemiology branch.

Patients should feel reassured, she added. "In general, the risks [of radiation therapy] are smaller than the benefits," she said.

The study, published online March 30 in The Lancet Oncology, is the first to quantify the cancer risks posed by radiation treatment for different malignancies.

Berrington de Gonzalez and colleagues collected data on 647,672 adult cancer survivors included in the U.S. Surveillance, Epidemiology and End Results cancer registries. All had survived five years or longer after cancer treatment, and follow-up ran from 1978 to 2007.

The researchers looked at outcomes for 15 different types of cancer for which radiation treatment is routine, including cancers of the rectum, larynx, lung, breast, cervix, testicles, prostate, eye and orbit, brain and thyroid.

Over the 30 years of follow-up, 9 percent of these participants developed a second cancer. Of these, about 3,300 (8 percent) might have been the result of radiation treatment, the study authors said.

Second cancers related to earlier radiation therapy varied by type, the researchers noted.

More than half of the second cancers developed in breast and prostate cancer survivors. Four percent of second cancers were in the eye, and 24 percent were cancer of the testicles, the researchers found.

Patients who had their initial cancer when young were at the greatest risk of developing a second cancer. Also at high risk were those whose organs received high doses of radiation. The likelihood of developing a secondary cancer increased over time.

When these data are put in perspective, the absolute risk for a second cancer is 3 in 1,000 over 10 years after radiation therapy and 5 in 1,000 over 15 years, Berrington de Gonzalez said.

"We know that radiation therapy can increase the risk of getting another cancer, but at the same time the benefits outweigh the risks," said Elizabeth Ward, national vice president for intramural research at the American Cancer Society.

Radiation therapy is an important and relatively safe treatment for cancer, she added.

Thanks to treatment advances, Ward said, radiologists today are better able to pinpoint treatment and limit exposure to healthy tissue than they were in the past.

Now, studies are needed to determine the cancer risks from newer radiation treatments, the authors noted.

Dr. Anthony D'Amico, chief of radiation oncology at Brigham and Women's Hospital in Boston, agreed that the NCI findings are encouraging.

"Despite people's concerns, radiation is relatively safe with regard to the issue of second cancers, because the number of cancers that result from it are very small," D'Amico said.

More information

For more information on radiation therapy, visit the U.S. National Cancer Institute .

(SOURCES: Amy Berrington de Gonzalez, Ph.D., investigator, radiation epidemiology branch, U.S. National Cancer Institute, Bethesda, Md.; Anthony D'Amico, M.D., Ph.D., chief, radiation oncology, Brigham and Women's Hospital, Boston; Elizabeth Ward, Ph.D., national vice president for intramural research, American Cancer Society, Atlanta; March 30, 2011, The Lancet Oncology, online)

Post a comment
Write a comment:

Related Searches